NC-003

The New Combination 3 (NC-003) clinical trial tested the BPaZ regimen, consisting of bedaquiline, PA-824, and pyrazinamide. The two-week study found that the BPaZ regimen killed more than 99% of TB bacteria over the course of 14 days, and that the treatment was safe.

Background:

Overview

The New Combination 3 (NC-003) clinical trial tested the BPaZ regimen, consisting of bedaquilinePA-824, and pyrazinamide. The two-week study found that the BPaZ regimen killed more than 99% of TB bacteria over the course of 14 days, and that the treatment was safe. The trial also tested multiple clofazimine-containing TB treatment regimens in combination with PA-824 and bedaquiline

About the New Treatment(s)

The treatments tested in the NC-003 were identified through the TB Alliance’s Preclinical Regimen Identification program as having the potential to substantially shorten and simplify TB treatment.

About the NC-003 trial

NC-003 contained multiple arms, testing various new potential TB regimens. It treats patients for 2 weeks and completed enrollment in 2013. The primary endpoint of this trial is the reduction sputum colony counts of TB on culture over a 2-week period. 

Timeline

NC-003 was completed in 2013 and results will be made available in 2014. These results include the performance of various combination regimens tested as well as data on the indvidual activity of clofizamine and pyrazinamide.

Additional resources

Phase 2

Trial Components

Regimens